Drug Patents owned by Tetraphase Pharms
1. List of Xerava drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10961190 | TETRAPHASE PHARMS | Crystalline forms of eravacycline |
Oct, 2037
(14 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8796245 | TETRAPHASE PHARMS | C7-fluoro substituted tetracycline compounds |
Aug, 2029
(6 years from now) | |
| US8906887 | TETRAPHASE PHARMS | C7-fluoro substituted tetracycline compounds |
Dec, 2030
(7 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Aug 27, 2023 |
| Generating Antibiotic Incentives Now (GAIN) | Aug 27, 2028 |
Drugs and Companies using ERAVACYCLINE DIHYDROCHLORIDE ingredient
NCE-1 date: 2027-08-28
Market Authorisation Date: 27 August, 2018
Treatment: Treatment of complicated intra-abdominal infections in patients 18 years of age and older
Dosage: POWDER;INTRAVENOUS
XERAVA family patents
15
United States
5
Japan
4
Korea, Republic of
4
China
4
European Union
3
Israel
3
Hong Kong
3
Argentina
3
Spain
3
Poland
3
Taiwan, Province of China
3
New Zealand
2
Denmark
2
Mexico
2
Slovenia
2
Hungary
2
Singapore
2
Croatia
2
Portugal
2
Cyprus
2
RS
1
Australia
1
Lithuania
1
Morocco
1
Philippines
1
Norway
1
Colombia
1
Brazil
1
Netherlands
1
San Marino
1
Luxembourg
1
Canada
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic